- Home
- GDEN vs RIGL Comparison
GDEN vs RIGL Comparison
Compare GDEN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEN | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | 504 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 763.2M | 628.4M |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GDEN | RIGL |
|---|---|---|
| Price | $28.53 | $30.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $32.25 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 311.8K | 301.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | ★ $634,911,000.00 | $294,282,000.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $2.87 | $12.75 |
| P/E Ratio | ★ N/A | $1.57 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $19.57 | $16.88 |
| 52 Week High | $32.74 | $52.24 |
Technical Indicators
Market Signals| Indicator | GDEN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 54.84 |
| Support Level | $28.30 | $28.08 |
| Resistance Level | $28.78 | $32.55 |
| Average True Range (ATR) | 0.39 | 1.21 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 75.90 | 49.24 |
Price Performance
Historical ComparisonAbout GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.